IPSEN (OTCMKTS:IPSEY) Sets New 12-Month High - Here's What Happened

Key Points

• IPSEN's stock reached a new 52-week high of $33.46 during mid-day trading, up 5.8% from its previous close of $31.62.
• The company announced a dividend increase to $0.2896 per share, reflecting a significant dividend yield of 97.0%.
• IPSEN is actively engaged in clinical trials for multiple treatments, including drugs for oncology and rare diseases, highlighting its ongoing product pipeline development.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $33.46 and last traded at $33.46, with a volume of 664 shares changing hands. The stock had previously closed at $31.62.

IPSEN Trading Up 1.0%

The stock's 50-day moving average is $31.05 and its two-hundred day moving average is $29.71.

IPSEN Increases Dividend

The business also recently announced a dividend, which was paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th were issued a $0.2896 dividend. This is an increase from IPSEN's previous dividend of $0.23. This represents a yield of 97.0%. The ex-dividend date was Monday, June 9th.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.